2024-02-06 09:52:32 ET
Summary
- Obe-cel continues to demonstrate comparative efficacy with fewer side effects to approved therapies.
- Thus, the company will likely gain its first market authorization in November.
- Autolus made several strong leadership hires with direct experience in M&A, oncology, and lupus, a new research area.
My initial coverage of Autolus Therapeutics ( AUTL ), now a $1 billion market cap clinical-stage biopharmaceutical company, rated it a Strong Buy for numerous positive catalysts for 2023 . Investors who heeded this tip were rewarded, as the stock has skyrocketed nearly 150% to a 52-week high of $7.45 since publication. Shares have dipped about 20% after the FDA required black box warnings (“BBW”) for certain cell therapies to reflect a risk of T-cell malignancies. Most of Autolus’ pipeline is directed against the referenced B-cell maturation antigen (BCMA) or CD19 targets (Figure 1). While it is bad news, these cancer risks have been known for some time, and the BBWs may have minimal impact on clinical practice. The pullback may present entry points; AUTL remains attractive due to a therapy that could be on the market late this year....
Read the full article on Seeking Alpha
For further details see:
Autolus Upgrades Leadership And Faces CAR-T Approval